Sanofi: positive results from study on Dupixent.
(CercleFinance.com) - Sanofi and Regeneron have announced the results for the study of phase 3 on Dupixent (dupilumab) in the treatment of in moderate-to-severe atopic dermatitis at a Congress held in Geneva.
This study targets adults who are inadequately controlled by cyclosporine A or who present an intolerance or contra-indication to the drug.
In the study, Dupixent, in association with dermocorticoids significantly improved indicators of the overall severity of the disease, cicactrisation of the skin, itching, and indicators for the quality of life reported by patients.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This study targets adults who are inadequately controlled by cyclosporine A or who present an intolerance or contra-indication to the drug.
In the study, Dupixent, in association with dermocorticoids significantly improved indicators of the overall severity of the disease, cicactrisation of the skin, itching, and indicators for the quality of life reported by patients.
Copyright (c) 2017 CercleFinance.com. All rights reserved.